Search

Displaying results 2111 - 2120 of 10000 in total
  1. Drug

    Lamivudine

    go.drugbank.com/drugs/DB00709
    ApprovedInvestigational

    A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring.

    Mixtures: N/A, N/A
  2. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment … Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.

  3. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    beginning of a new wave of treatment options for patients suffering from insomnia. … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

  4. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.

  5. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    [A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG. … Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction

  6. Drug

    Depreotide

    go.drugbank.com/drugs/DB11628
    ApprovedWithdrawn

    Depreotide is an ingredient in the EMA-withdrawn product NeoSpect.

  7. Drug

    Stannous fluoride

    go.drugbank.com/drugs/DB11092
    ApprovedInvestigational

    It is an FDA-approved over-the-counter product. … Although similar in function and activity to Sodium Fluoride (NaF), the conventionally added ingredient in toothpastes, stannous fluoride has been shown to be more effective at stopping and reversing dental

    Categories: Compounds used in a research, industrial, or household settingProducts: Crest Pro-Health With a Touch of Scope, Crest Pro Health with a Touch of Scope
  8. Drug

    Polymyxin B

    go.drugbank.com/drugs/DB00781
    ApprovedInvestigationalVet approved

    Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line[A176429].

    Mixtures: Bacitracin-N Ointment, Pomada De La Campana Triple Antibiotic Pain Relief
  9. Drug

    Seproxetine

    go.drugbank.com/drugs/DB06731
    Experimental

    It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. … Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.

  10. Drug

    Vinflunine

    go.drugbank.com/drugs/DB11641
    ApprovedInvestigational

    While these patients have a median survival of approximately 4 months and a poor prognosis [L1396], there is currently no standard therapy in patients with advanced urothelial carcinoma [A32626]. … Like other vinca agents, vinflunine is an anti-mitotic agent that induces a cell cycle arrest at the G2/M phase and promotes cell death via apoptosis [L1396].

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index